The respiration-linked limiting step of tumor cell transition from the non-cycling to the cycling state: its inhibition by oxidizable substrates and its relationships to purine metabolism.
The recruitment into the cycling state of resting Yoshida AH 130 hepatoma cells was studied with respect to its dependence on respiration in an experimental system wherein the overall energy requirement for this recruitment can be supplied by the glycolytic ATP. The G1-S transition of these cells, unaffected by 2,4-dinitrophenol (DNP) at concentrations which uncouple the respiratory phosphorylation, is impaired either by blocking the electron flow to oxygen by antimycin A or by adding an excess of some oxidizable substrates, chiefly pyruvate and oxalacetate. An experimental analysis, focused on pyruvate activity, showed that the inhibition of cell recruitment into S is not related to the depressing effects of this substrate on aerobic glycolysis of tumor cells, nor is it modified by forcing, in the presence of DNP, pyruvate oxidation through the tricarboxylic acid cycle as well as the overall oxygen consumption. Addition of suitable concentrations of preformed purine bases (mainly adenine), completely removes the block of the G1-S transition produced either by the excess of oxidizable substrates or by antimycin A. These findings indicate the existence of a respiration-linked step in purine metabolism, which restricts the above transition and is equally impaired by blocking the respiratory chain or by saturating it with an excess of reducing equivalents derived from unrelated oxidations. The inhibitory effects of pyruvate and antimycin A can be largely removed by the addition of folate and tetrahydrofolate, suggesting that the respiration-linked restriction point of tumor cell cycling involves the folate metabolism and its connections to purine synthesis.
D000225:Adenine / Q000494:pharmacology; D000818:Animals; D000968:Antimycin A / Q000494:pharmacology; D005492:Folic Acid / Q000494:pharmacology; D006019:Glycolysis; D007399:Interphase / Q000187:drug effects; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology*; D010071:Oxaloacetates / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects; D011687:Purines / Q000378:metabolism*; D011773:Pyruvates / Q000378:metabolism / Q000494:pharmacology; D019289:Pyruvic Acid; D051381:Rats; D011919:Rats, Inbred Strains; D013763:Tetrahydrofolates / Q000494:pharmacology
D010071:Oxaloacetates; D011687:Purines; D011773:Pyruvates; D013763:Tetrahydrofolates; C030371:5,6,7,8-tetrahydrofolic acid; D000968:Antimycin A; D019289:Pyruvic Acid; D005492:Folic Acid; D000225:Adenine